Great paper showing utility of tumor fraction in liquid biopsy complete with therapy decisions in a real world setting aacrjournals.org/clincancerres/…
#LCSM Christian Rolfo

Thanks Stephen! looking forward to seeing the magnitude of benefit hoping we can make a real impact in patients with more limited stage SCLC #LCSM

bit.ly/DEI-S please take this important IASLC survey #LCSM

Agree a great editorial! #LCSM

Congratulations Jill! Well earned!!! Thanks for all you do #LCSM

Take IASLC's Biomarker Testing Survey to help learn the steps to solve some of the hurdles we have seen with biomarker testing of NSCLC The survey is available in 6 languages & takes just a few minutes. bit.ly/BiomarkerS24 #LCSM IASLC

Amazing effort for which Dr Florez lead the way #LCSM IASLC

Congratulations on your work to get this approval!

Excited to share the first presentation of the preliminary activity and safety results on NVL-655, new ALK TKI. Brief recap here. Efficacy in heavily pretreated ALK+ NSCLC. Thanks to AACR #Targets23 for the opportunity to present, to collaborators, patients ALK Positive #LCSM

A great event promoting breast and lung cancer screening! RUSH Cancer Center RUSH RUSH Department of Surgery

Less than one week left to share your research at IASLC #NACLC23 ! We welcome both LBA and Regular Abstracts. Make your mark on #lungcancer treatment development – and submit by 10/3/23. Let's make a difference together! Learn more & submit: ow.ly/c51c50PQMP5 #LCSM

Great international congress. Join IASLC in the fight against lung cancer. Reception yesterday after the opening ceremony was great with traditional music and dance from Singapore. Become an IASLC member. #WCLC23 IASLC ASCO ESMO - Eur. Oncology FLASCO @FAUMedSchool The Oncology Institute

I do think the benefit of adding carbo pemetrexed to osimertinib in patients with CNS disease is compelling. Would like to see thoughts from patient perspective and can’t wait to see the correlative data @iaslc EGFR Resisters #LCSM

Amazing introduction and amazing talk by Jill Feldman and Princess Mired around global access to lung cancer treatments and tobacco control. Inspiring. #WCLC23 IASLC Jill Feldman

⏳LAST CHANCE ⏳

Submit your abstract for the #EGFR Summit - DEADLINE TODAY ➡️ce.ceconcepts.com/EGFR23

Jill Feldman Ivy Elkins Zosia Piotrowska Helena Yu Joshua Sabari, MD Mary Jo Fidler Christine Lovly, MD, PhD Stephen V Liu, MD @egfrresisters @CEC_onc #LCSM #EGFR

Edgardo S. Santos, M.D., FACP, FASCO
Dr. Luis E. Raez
GO2 for Lung Cancer
KRASKickers
EGFR Resisters
ALK+ International
NTRKers
RETpositive
FLASCO
The ROS1ders, Inc.
Maroone Cancer at Cleveland Clinic Florida
twitter.com/edgardo_ny/sta…

Outstanding discussion done by Dr. Joshua Sabari who dissected all data from KRASG12C plus chemo, data on JDQ443 novel inh and the biomaker analysis from CodeBreak 200. I rec to watch this presentatio again. Joshua Sabari, MD IASLC ASCO #ASCO2023 FLASCO Ferdinandos Skoulidis KRASKickers

So much interesting data in EGFR mutated lung cancer at ASCO23! Be a part of the progress! trainees and early faculty can apply for the ow.ly/nwbe50OvmV7 Ivy Elkins Jill Feldman #LCSM Abstract submission deadline later this summer #ASCO23

Nice biomarker studies for CHOICE -01 Toripalimab vs placebo with platinum doublet and high crossover leading to good results in the squamous cell population Coherus BioSciences #LCSM #ASCO23

Long awaited FLAURA2 results👇
Why's this impt for #EGFRm #lungcancer ?
Treatment (Osi) w/a median response of 19mth is NOT enough.
Look forward to seeing the data
My tweet yesterday (chemo after Osi) stands, but combo chemo/Osi 1st is even BETTER!
#LCSM EGFR Resisters OncoAlert